Related Experiment Video

Updated: Oct 20, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.4K

Bedside testing of CYP2C19 vs. conventional clopidogrel treatment to guide antiplatelet therapy in ST-segment

Abdullah M Al-Rubaish1, Fahad A Al-Muhanna1, Abdullah M Alshehri1

  • 1Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.

International Journal of Cardiology
|September 10, 2021
PubMed

Insights

Genotype-guided P2Y12 inhibitor selection in ST-segment elevation myocardial infarction (STEMI) patients significantly reduced ischemic and bleeding events. This strategy optimizes antiplatelet therapy compared to standard clopidogrel treatment.

Area of Science:

  • Cardiology
  • Pharmacogenomics
  • Clinical Trials

Background:

  • Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is standard for ST-segment elevation myocardial infarction (STEMI).
  • Clopidogrel, a common P2Y12 inhibitor, provides sub-optimal platelet inhibition in up to one-third of patients.
  • CYP2C19 genetic variations influence clopidogrel's efficacy.

Purpose of the Study:

  • To investigate the efficacy of a CYP2C19 genotype-guided strategy for selecting P2Y12 inhibitors in STEMI patients.
  • To compare the outcomes of genotype-guided therapy versus standard clopidogrel treatment.

Main Methods:

  • Prospective randomized clinical trial involving 755 STEMI patients.
  • Patients were genotyped for CYP2C19 loss-of-function alleles.
  • Genotype-guided group: ticagrelor for carriers, clopidogrel for non-carriers. Standard group: clopidogrel for all.

Main Results:

  • The genotype-guided group (383 patients) showed a significantly lower risk of the primary composite outcome (ischemic and bleeding events) compared to the standard group (372 patients) (OR 0.34).
  • Significant reductions were observed in recurrent myocardial infarction (OR 0.25), cardiovascular death (OR 0.16), and major bleeding (OR 0.49) in the genotype-guided group.
  • No significant difference in stent thrombosis rates between groups (OR 0.85).

Conclusions:

  • A genotype-guided P2Y12 inhibitor escalation strategy is feasible for STEMI patients undergoing percutaneous coronary intervention (PCI).
  • This pharmacogenomic approach significantly reduces major adverse cardiovascular and bleeding events compared to conventional antiplatelet therapy.
Abstract

Keywords:
CYP2C19ClopidogrelP2Y12 inhibitorPCISTEMITicagrelor

More Related Videos

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.4K
Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.2K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
764
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
71
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
47
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
49
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
66
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
54